Basilea announces divestment of its Chinese R&D subsidiary to PHT International
- Wall Street ends lower as investors await earnings, inflation data
- Microsoft (MSFT) announces $19.7 billion acquisition of Nuance (NUAN)
- Dollar drops as traders prepare for inflation data
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
Basel, Switzerland, February 15, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement to divest its Chinese research and development (R&D) subsidiary Basilea Pharmaceutica China Ltd. (“BPC”), by selling BPC’s parent company BPh Investitionen Ltd. to the U.S.-based custom manufacturing organization PHT International Inc. (“PHT”). This will increase flexibility in sourcing R&D services in the future. All 72 employees and the facilities will be transferred to PHT. The initial payment is USD 2.5 million, which will be due upon closing of the transaction, which is expected in the second quarter of 2021 subject to customary closing conditions. Basilea is entitled to additional payments of USD 3.8 million over the course of the next three years, for a total purchase price of USD 6.3 million.
David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with this transaction, which will increase our flexibility in sourcing external R&D services for our growing portfolio, while optimizing our future cost structure. Importantly, PHT has committed to maintaining R&D services through the existing site in China to Basilea. This ensures continued seamless support for our ongoing R&D projects and allows us to continue to benefit from the expertise that we have built in our Chinese organization over the course of the last two decades.”
Dr. Laurenz Kellenberger, Basilea’s Chief Scientific Officer and Chairman of BPC, added: “Since we founded BPC in 2002, our Chinese colleagues have been a great support for our R&D projects and I would like to thank them for their valuable contributions. We are convinced that their expertise will be even better leveraged within a structure that is entirely focused on providing contract research, development and manufacturing services such as PHT. We wish them all the best for the future and are looking forward to continue working with them on our projects.”
PHT International Inc. is a privately owned custom manufacturing organization for chemicals for the pharmaceutical industry and other sectors. PHT was founded in 1993 and is headquartered in Charlotte, North Carolina, USA. PHT has five locations in China.
Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and infectious diseases. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com.
About Basilea Pharmaceutica China
Basilea Pharmaceutica China Ltd. (BPC) was founded in 2002 and is located in the Haimen Economic-Technological Development Zone of Nantong city, Jiangsu, a ninety minutes’ drive from Shanghai. Operating in an innovative R&D environment, the company builds on its highly qualified, well-trained and experienced professionals as well as a state-of-the-art scientific and technical infrastructure. BPC focuses on the chemical synthesis and analysis of complex molecules, analytical development and process research and development, so as to provide R&D services to worldwide customers.
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd. and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
| Peer Nils Schröder, PhD|
Head of Corporate Communications & Investor Relations
|Phone||+41 61 606 1102|
This press release can be downloaded from www.basilea.com.
Press release (PDF)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PenderFund Capital Management Ltd Responds to Proposed Acquisition of The Leaf Group
- Podcast Downloads in Australia Reach 50 Million in March 2021
- Canadian Pacific, Kansas City Southern Assert Right to Have Transaction Reviewed Under Waiver Granted to KCS in 2001